Moreover, the overexpression of FGFR2b was also frequently seen in metastatic lymph node tissue; therefore, both primary and metastatic gastric cancer tissue should be examined to select patients with GC for treatment with FGFR2 inhibitors [120]. This evidence concerns the gene FGFR2 and gastric cancer.